Lupin eyes deals up to $1B in growth push; NJ wins grant to retrain laid-off pharma workers;

@FiercePharma: India's Lupin joins hunt for branded products to beef up a generics portfolio. Has $1B to spend. Report | Follow @FiercePharma

@EricPFierce: Bayer & Merck have weighed in on the big pay-for-delay case that the Supreme Court takes up this month. More | Follow @EricPFierce

> Lupin is eyeing a pediatric drug brand in the U.S. and a generics company in Brazil as it shops for assets to beef up its sales. Report

> The Federal Trade Commission argues that generic drugmakers should have access to samples of the drugs they're trying to copy, even if those drugs fall under a risk-management plan. Report

> New Jersey won a federal grant to incentivize companies to hire former pharmaceutical industry workers; the money will pay for training and subsidize salaries. Report

> Florida economic development officials approved a $500,000 incentive package to help attract a Venezuelan drugmaker and 100 jobs to the state. Report

> To continue to grow in a crowded generics market, Indian drugmakers need to focus on new drug-delivery devices and technologies, as well as other types of "super-generics," experts say. Report

> A top Cipla Medpro shareholder said it would ask India's Cipla to hike its buyout offer past the current $500 million. Report

Medical Device News

 @FierceMedDev: For GenMark, more flu was good news in 2012. More | Follow @FierceMedDev

 @MarkHFierce: France's EyeTechCare, with $13M in new funding, will pursue U.S. approval of its glaucoma ultrasound medical device. More | Follow @MarkHFierce

 @DamianFierce: Luminex is on board to handle companion diagnostics for Merck's blockbuster hopeful Alzheimer's drug. More | Follow @DamianFierce

> Analysts: Life Tech's suitors may balk at $15B price tag. More

> Zoll wins German patent battle over intravascular temperature management tech. More

Biotech News

 @FierceBiotech: Editor's corner: Will biotech grow in China and India without much VC help? More | Follow @FierceBiotech

@JohnCFierce: Weird deal. Receptos gets a PhII-ready AbbVie antibody. AbbVie has option to co-dev, co-promote. If it's worth anything, why farm it out? | Follow @JohnCFierce

@RyanMFierce: Takeda expanded a discovery alliance with Sripps Florida (pharma outsourcing more discovery work to academics.) Release | Follow @RyanMFierce

> J&J opens new innovation center in quest for more early-stage deals. Story

> Domain opens shop in China with plans to seed biotech startups, do deals. News

Drug Delivery News

@MichaelGFierce: Vaginal nanogel with bee venom could prevent HIV infection. Story | Follow @MichaelGFierce

> Terumo evens with Abbott's Xience in drug-eluting stent study. News

> Study: Artificial pancreas improves overnight care in diabetic children. Article

> Shape-shifting proteins could aid drug delivery for cancer, infections. More

> Celgene drops $13M on Presage's 3-D drug delivery platform. Report

And Finally... Heart patients may be prescribed too many drugs, and eliminating some may improve care, cardiologists say. Report

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.